Ibotta, Inc. (IBTA)

NYSEInformation TechnologySoftware - ApplicationSnapshot 2026-10-23

$48.61-0.59%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Ibotta, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
EBITDA	$12M–$14Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	93.36M
EPS	—	-0.1
FY 2026 · Annual
Revenue	—	353.35M
EPS	—	-0.663
FY 2027 · Annual
Revenue	—	384.72M
EPS	—	-0.275

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EBITDA margin improves despite revenue pressure	A primary condition in Ibotta, Inc.'s published investment case. The stated target is margin improves from current levels over next 4 quarters.	Under Pressure	margin fails to improve or declines over next 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Adjusted EBITDA margin improved from 11% in 2026-Q1 to 18.6% in 2026-Q2, with adjusted EBITDA rising from $8.7 million to $16.5 million. Management's focus on margin improvement is delivering clear progress. Delivery assessment Oct 24, 2026
Revenue stabilizes near $82M and grows modestly	A primary condition in Ibotta, Inc.'s published investment case. The stated target is >= $82 million next 4 quarters.	Intact	revenue falls below $82 million next 4 quarters	Revenue: $88.905M FY2026-Q2; GAAP. Published target: >= $82 million next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 4, 202688,905,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c236be1c-f16f-4123-86e7-2b84d55b88b5. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $82.5 million in 2026-Q1 (down 2% YoY) to $88.9 million in 2026-Q2 (up 3% YoY), with redemption revenue growing 10% YoY in 2026-Q2. Management emphasized returning to year-over-year growth ahead of schedule, indicating delivering trajectory. Delivery assessment Oct 24, 2026
Share repurchase program expands by $100 million	It also expanded its share buyback program by $100 million.	Intact	no expansion of buyback program by mid-2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management repurchased 1.9 million shares for $44.7 million in 2026-Q1 and 0.7 million shares for $23.0 million in 2026-Q2, totaling 2.6 million shares for $67.7 million. The share repurchase program is actively executed as stated. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.38B

$0.38B → $0.38B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$376,661,680	3 / 8
2026-07-25	Unavailable	$376,663,934	3 / 5
2026-07-26	Unavailable	$376,661,680	3 / 8
2026-07-27	Unavailable	$376,663,934	3 / 5
2026-07-28	Unavailable	$376,661,680	3 / 8
2026-07-29	Unavailable	$376,661,680	3 / 8
2026-07-30	Unavailable	$376,663,934	3 / 5
2026-07-31	Unavailable	$376,661,680	3 / 8
2026-08-01	Unavailable	$376,663,934	3 / 5
2026-08-02	Unavailable	$376,661,680	3 / 8
2026-08-03	Unavailable	$376,661,680	3 / 8
2026-08-04	Unavailable	$376,661,680	3 / 8
2026-08-05	Unavailable	$376,661,680	3 / 8
2026-08-06	Unavailable	$381,259,640	3 / 7
2026-08-07	Unavailable	$383,613,640	3 / 5
2026-08-08	Unavailable	$383,613,640	3 / 5
2026-08-09	Unavailable	$383,611,640	3 / 9
2026-08-10	Unavailable	$383,613,640	3 / 5
2026-08-12	Unavailable	$383,611,640	3 / 9
2026-08-13	Unavailable	$383,613,640	3 / 5
2026-08-14	Unavailable	$383,613,640	3 / 5
2026-08-15	Unavailable	$383,613,640	3 / 5
2026-08-16	Unavailable	$383,613,640	3 / 6
2026-08-17	Unavailable	$383,613,640	3 / 6
2026-08-18	Unavailable	$383,613,640	3 / 6
2026-08-19	Unavailable	$383,613,640	3 / 6
2026-08-20	Unavailable	$383,613,640	3 / 6
2026-08-21	Unavailable	$383,613,640	3 / 6
2026-08-22	Unavailable	$385,825,595	3 / 6
2026-08-23	Unavailable	$385,825,595	3 / 6
2026-08-24	Unavailable	$385,825,595	3 / 6
2026-08-25	Unavailable	$385,825,595	3 / 6
2026-08-26	Unavailable	$385,825,595	3 / 6
2026-08-27	Unavailable	$385,825,595	3 / 6
2026-08-28	Unavailable	$385,825,595	3 / 6
2026-08-29	Unavailable	$385,825,595	3 / 6
2026-08-30	Unavailable	$385,825,595	3 / 6
2026-08-31	Unavailable	$385,825,595	3 / 6
2026-09-01	Unavailable	$385,825,595	3 / 6
2026-09-02	Unavailable	$385,825,595	3 / 6
2026-09-03	Unavailable	$385,825,595	3 / 6
2026-09-04	Unavailable	$385,825,595	3 / 6
2026-09-05	Unavailable	$385,825,595	3 / 6
2026-09-06	Unavailable	$385,825,595	3 / 6
2026-09-07	Unavailable	$385,825,595	3 / 6
2026-09-08	Unavailable	$385,825,595	3 / 6
2026-09-09	Unavailable	$385,825,595	3 / 6
2026-09-10	Unavailable	$385,825,595	3 / 6
2026-09-11	Unavailable	$385,825,595	3 / 6
2026-09-12	Unavailable	$385,825,595	3 / 6
2026-09-13	Unavailable	$385,825,595	3 / 6
2026-09-14	Unavailable	$385,825,595	3 / 6
2026-09-15	Unavailable	$385,825,595	3 / 6
2026-09-16	Unavailable	$385,825,595	3 / 6
2026-09-17	Unavailable	$385,825,595	3 / 6
2026-09-18	Unavailable	$385,825,595	3 / 6
2026-09-19	Unavailable	$385,825,595	3 / 6
2026-09-20	Unavailable	$385,825,595	3 / 6
2026-09-21	Unavailable	$385,825,595	3 / 6
2026-09-22	Unavailable	$385,825,595	3 / 6
2026-09-23	Unavailable	$385,825,595	3 / 6
2026-09-24	Unavailable	$385,825,595	3 / 6
2026-09-25	Unavailable	$384,722,751	3 / 6
2026-09-26	Unavailable	$384,722,751	3 / 6
2026-09-27	Unavailable	$384,722,751	3 / 6
2026-09-28	Unavailable	$384,722,751	3 / 6
2026-09-29	Unavailable	$384,722,751	3 / 6
2026-09-30	Unavailable	$384,722,751	3 / 6
2026-10-01	Unavailable	$384,722,751	3 / 6
2026-10-02	Unavailable	$384,722,751	3 / 6
2026-10-03	Unavailable	$384,722,751	3 / 6
2026-10-04	Unavailable	$384,722,751	3 / 6
2026-10-05	Unavailable	$384,722,751	3 / 6
2026-10-06	Unavailable	$384,722,751	3 / 6
2026-10-07	Unavailable	$384,722,751	3 / 6
2026-10-08	Unavailable	$384,722,751	3 / 6
2026-10-09	Unavailable	$384,722,751	3 / 6
2026-10-10	Unavailable	$384,722,751	3 / 6
2026-10-11	Unavailable	$384,722,751	3 / 6
2026-10-12	Unavailable	$384,722,751	3 / 6
2026-10-13	Unavailable	$384,722,751	3 / 6
2026-10-14	Unavailable	$384,722,751	3 / 6
2026-10-15	Unavailable	$384,722,751	3 / 6
2026-10-16	Unavailable	$384,722,751	3 / 6
2026-10-17	Unavailable	$384,722,751	3 / 6
2026-10-18	Unavailable	$384,722,751	3 / 6
2026-10-19	Unavailable	$384,722,751	3 / 6
2026-10-20	Unavailable	$384,722,751	3 / 6
2026-10-21	Unavailable	$384,722,751	3 / 6
2026-10-22	Unavailable	$384,722,751	3 / 6
2026-10-23	Unavailable	$384,722,751	3 / 6
2026-10-24	Unavailable	$384,722,751	3 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	6	2
2026-06-01	1	6	2
2026-07-01	1	6	2
2026-08-01	1	6	2
2026-09-01	1	6	2
2026-10-01	1	6	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 6 Hold · 2 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EBITDA margin improves despite revenue pressurePublished status: Under Pressure
Revenue stabilizes near $82M and grows modestlyRevenue: $88.905M
Share repurchase program expands by $100 millionDirect metric needs a verified mapping

Next proof point

Nov 2, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-45.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ibotta, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk growth and execution story, not a proven durable compounder. The multi-year view is on watch: management priorities are showing progress, while recent financial performance remains weak and confidence has eased to medium.

What's priced into Ibotta, Inc.

IBTA is valued at a substantial premium to peers, and the evidence labels that premium unjustified. The expectations gap is 0.38, with a re-rating identified as the main valuation driver, but the snapshot does not spell out the market’s specific growth assumptions.

What the fundamentals likely do

Near-term results show improving momentum: second-quarter revenue grew year over year, adjusted EBITDA margin improved, and publisher redemptions expanded. These gains support management’s stated priorities, but recent earnings misses and elevated risk of another miss leave the next quarter uncertain.

What Ibotta, Inc. hinges on

The multi-year thesis hinges on revenue growth continuing, margins improving, and network expansion translating into sustained business progress. Near term, a guidance cut or another earnings miss would weaken the case; continued strength from sector peers or easier interest rates could provide a more supportive backdrop.